Suppr超能文献

儿童炎症性肠病的营养状况、身体成分及生长发育的最新进展

Update on nutritional status, body composition and growth in paediatric inflammatory bowel disease.

作者信息

Hill Rebecca J

机构信息

Rebecca J Hill, Children's Nutrition Research Centre, Queensland Children's Medical Research Institute, The University of Queensland, Herston, Qld 4029, Australia.

出版信息

World J Gastroenterol. 2014 Mar 28;20(12):3191-7. doi: 10.3748/wjg.v20.i12.3191.

Abstract

Growth and nutritional status are important issues in paediatric inflammatory bowel disease (IBD). While linear growth is easy to assess, nutritional status is more complicated, with reports often compromised by the use of simple measures, such as weight and the body mass index, to assess nutritional status rather than more appropriate and sophisticated techniques to measure body composition. This review is an update on what is currently known about nutritional status as determined by body composition in paediatric IBD. Further, this review will focus on the impact of biologics on growth in paediatric IBD. Significant lean mass deficits have been reported in children with IBD compared with controls, and there is evidence these deficits persist over time. Furthermore, data imply that gender differences exist in body composition, both at diagnosis and in response to treatment. With respect to growth improvements following treatment with biologics, there are conflicting data. While some studies report enhancement of growth, others do not. The relationship between disease severity, impaired growth and the requirement for biologics needs to be considered when interpreting these data. However, key features associated with improvements in growth appear to be successful clinical response to treatment, patients in early stages of puberty, and the presence of growth failure at the onset of treatment.

摘要

生长和营养状况是小儿炎症性肠病(IBD)中的重要问题。虽然线性生长易于评估,但营养状况更为复杂,报告往往因使用体重和体重指数等简单指标来评估营养状况,而非采用更合适、更精密的技术来测量身体成分而受到影响。本综述是关于小儿IBD中由身体成分所确定的营养状况的现有认知的更新。此外,本综述将聚焦生物制剂对小儿IBD生长的影响。与对照组相比,IBD患儿已报告存在显著的瘦体重不足,且有证据表明这些不足会随着时间持续存在。此外,数据表明在诊断时以及对治疗的反应方面,身体成分存在性别差异。关于生物制剂治疗后的生长改善情况,数据存在矛盾。虽然一些研究报告生长得到增强,但其他研究则不然。在解读这些数据时,需要考虑疾病严重程度、生长受损与生物制剂需求之间的关系。然而,与生长改善相关的关键特征似乎是对治疗的成功临床反应、处于青春期早期的患者以及治疗开始时存在生长衰竭。

相似文献

8
Nutritional support for pediatric patients with inflammatory bowel disease.炎症性肠病患儿的营养支持
J Pediatr Gastroenterol Nutr. 1989 Jan;8(1):8-12. doi: 10.1097/00005176-198901000-00003.
9
Crohn's disease and growth deficiency in children and adolescents.儿童和青少年的克罗恩病与生长发育迟缓
World J Gastroenterol. 2014 Oct 7;20(37):13219-33. doi: 10.3748/wjg.v20.i37.13219.
10
Problems in diagnosis of IBD in children.儿童炎症性肠病的诊断问题。
Neth J Med. 1997 Feb;50(2):S8-11. doi: 10.1016/s0300-2977(96)00064-2.

引用本文的文献

4
6
Biological Effects and Applications of Chitosan and Chito-Oligosaccharides.壳聚糖和壳寡糖的生物学效应及应用
Front Physiol. 2019 May 7;10:516. doi: 10.3389/fphys.2019.00516. eCollection 2019.
7
Conceptual Model of Lean Body Mass in Pediatric Inflammatory Bowel Disease.儿童炎症性肠病中去脂体重的概念模型。
J Pediatr Gastroenterol Nutr. 2019 Mar;68(3):301-305. doi: 10.1097/MPG.0000000000002212.

本文引用的文献

9
Mechanisms of growth impairment in pediatric Crohn's disease.儿童克罗恩病生长发育受损的机制
Nat Rev Gastroenterol Hepatol. 2009 Sep;6(9):513-23. doi: 10.1038/nrgastro.2009.124.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验